Neoantigen-based vaccines showed promising results in terms of neoantigen-specific CD4 and CD8 T cell responses and survival in both melanoma (175, 176) and glioblastoma (177, 178), suggesting a potential benefit in other cancers including CRC. This evidence concerns the gene CD4 and colorectal carcinoma.